DNMT3A and acute myeloid leukemia: established a prognostic nomogram characterized by white blood cell count (≥10×109/L at diagnosis), mutated DNMT3A, and genes involved in signaling pathways, which divided int AML into two subgroups that could predict that the high-risk subgroup was associated with inferior OS and relapse-free survival (RFS), whereas allo-HSCT reduced the relapse risk of high-risk patients (3-year RFS: allo-HSCT: 40.0 vs. chemotherapy, P = 0.010) (19).